Advisory panel gives thumbs down to Alzheimer's test

Why This Topic Matters

It helps readers understand a Medicare coverage controversy involving diagnostic imaging for dementia evaluation and signals possible changes in how CMS gathers evidence and shapes coverage policy for new services.

Article Sections

1. Medicare review of PET scanning for suspected Alzheimer's disease

   Discusses the advisory panel's review of PET use in suspected Alzheimer's disease and the broader Medicare coverage context for imaging services. The section focuses on the policy setting and the evidence review process.

2. Clinical evidence and testimony on diagnostic value

   Summarizes the types of clinical evidence and stakeholder testimony considered by the committee. It also covers the broader discussion of diagnosis, treatment, and the limits of current therapy options.

3. MCAC panels could be given broader role

   Describes CMS interest in expanding the kinds of coverage questions posed to advisory panels. The section outlines general areas where CMS may seek more input on new technologies and treatments.